Determination of Residual Anticoagulatory Effects of Prophylactic or Therapeutic Treatment With Fondaparinux

Johann Wolfgang Goethe University Hospital1 个研究点分布在 1 个国家目标入组 110 人开始时间: 2010年4月最近更新: 2010年4月13日

适应症

试验速览

阶段: 不适用
发起方
入组人数: 110
试验地点: 1
主要终点: antiXa-levels (peak- and through-levels)

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to determine residual anticoagulatory effects of a prophylactic or therapeutic fondaparinux treatment i.e. prior to surgery/intervention, after pause of therapy etc.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Fondaparinux therapy for at least 3 days

排除标准

•Age < 18 years
•Hemodialysis

结局指标

主要结局

antiXa-levels (peak- and through-levels)

时间窗: between day 3 and day 14 after start of therapy

次要结局

thromboembolic or bleeding episodes, HIT(day 14 after start of therapy)

研究者

发起方

Johann Wolfgang Goethe University Hospital

申办方类型

Other

研究点 (1)

Loading locations...

相似试验

终止

4 期

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)COVID-19

NCT04406389Weill Medical College of Cornell University14

尚未招募

不适用

Assessing the correlations of anticoagulant effects between Thromboelastography [TEG] and anti-Xa activity in patients on therapeutic dose of low-molecular-weight heparin (LMWH)?Blood - Other blood disordersAcute coronary syndrome

ACTRN12609000055202Hayden White60

已完成

不适用

Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care UnitsCovid19

NCT04829552William Beaumont Hospitals704

招募中

3 期

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGBleedingStrokeAtrial Fibrillation

NCT04045665Icahn School of Medicine at Mount Sinai3,200

已完成

4 期

Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19COVID-19Venous ThrombosesArterial Thrombosis

NCT04367831Columbia University94